Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study

JmjC domain-containing protein 6 (JMJD6) has been thought as a potential target for various diseases particularly cancer. However, few selective JMJD6 inhibitors have been reported. In this investigation, molecular docking and biological activity evaluation were performed to retrieve new JMJD6 inhibitors, which led to the identification of a hit compound, J2. Further structural optimization and structure-activity relationship (SAR) analysis towards J2 were carried out, which gave a new potent JMJD6 inhibitor, 7p. This compound showed an IC50 value of 0.681 mu M against JMJD6, but displayed no activity against other tested JmjC domain-containing protein family members, indicating good selectivity (>100 fold). Collectively, this investigation offers a selective JMJD6 inhibitor, which could be taken as a lead compound for subsequent drug discovery targeting JMJD6.

Automated summary

This study identified a selective JMJD6 inhibitor through molecular docking and biological activity evaluation, and successfully optimized a new potent inhibitor 7p. The inhibitor showed strong inhibition against JMJD6 with good selectivity (>100 fold) against other JmjC domain-containing protein family members.